Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 11/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.49 |
| ▸ | HTR2A | P28223 | 4/20 | 0.49 |
| ▸ | DRD3 | P35462 | 4/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.49 |
| ▸ | DRD2 | P14416 | 3/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.49 |
| ▸ | HRH1 | P35367 | 3/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.49 |
| ▸ | HTR2B | P41595 | 2/20 | 0.49 |
| ▸ | MLNR | O43193 | 1/20 | 0.49 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Draflazine SCHEMBL7705425 | 1.00 | SLC29A1 (1.00) | SLC29A1KCNH2SLC6A3HTR2ADRD3 | |
| Draflazine SCHEMBL9362256 | 0.99 | SLC29A1 (0.98) | SLC29A1KCNH2SLC6A3HTR2ADRD3 | |
| Draflazine SCHEMBL9410932 | 0.99 | SLC29A1 (0.98) | SLC29A1KCNH2SLC6A3HTR2ADRD3 | |
| Hydrochloric Acid SCHEMBL9808242 | 0.93 | SLC29A1 (0.86) | SLC29A1KCNH2SLC6A3HTR2ADRD3 | |
| SCHEMBL10458587 | 0.92 | SLC29A1 (0.85) | SLC29A1KCNH2SLC6A3HTR2ADRD3 | |
| SCHEMBL10460454 | 0.92 | SLC29A1 (0.85) | SLC29A1KCNH2SLC6A3HTR2ADRD3 | |
| SCHEMBL9808240 | 0.91 | SLC29A1 (0.84) | SLC29A1KCNH2SLC6A3HTR2ADRD3 | |
| SCHEMBL10458592 | 0.91 | SLC29A1 (0.84) | SLC29A1KCNH2SLC6A3HTR2ADRD3 | |
| SCHEMBL9808247 | 0.90 | SLC29A1 (0.82) | SLC29A1KCNH2SLC6A3HTR2ADRD3 | |
| SCHEMBL10460327 | 0.90 | SLC29A1 (0.82) | SLC29A1KCNH2SLC6A3HTR2ADRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 290 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025074343-A2 | PRODRUGS OF HUMAN DIHYDROOROTATE DEHYDROGENASE (hDHODH) INHIBITORS | DRUG DISCOVERY AND CLINIC S.R.L. (IT) | 2025-04-10 | — | — | WO | claimed |
| US-20230414575-A1 | MK2 ACTIVATING COMPOUNDS FOR USE IN TREATING VASCULAR LEAK AND ENDOTHELIAL BARRIER DISORDERS | AKTTYVA THERAPEUTICS INC (US) | 2023-12-28 | — | — | US | claimed |
| EP-4244341-A2 | MK2 ACTIVATING COMPOUNDS FOR USE IN TREATING VASCULAR LEAK AND ENDOTHELIAL BARRIER DISORDERS | Akttyva Therapeutics, Inc. (US) | 2023-09-20 | — | — | EP | claimed |
| WO-2022104097-A2 | MK2 ACTIVATING COMPOUNDS FOR USE IN TREATING VASCULAR LEAK AND ENDOTHELIAL BARRIER DISORDERS | AKTTYVA THERAPEUTICS, INC. (US) | 2022-05-19 | — | — | WO | claimed |
| EP-2459227-B1 | Prodrugs containing an aromatic amine connected by an amide bond to a carrier | ASCENDIS PHARMA AS (DK) | 2021-03-17 | — | — | EP | claimed |
| CN-110214009-A | Dipyridamole is for treating SLC29A2 core-expression cancer | 中央研究院 | 2019-09-06 | — | — | CN | claimed |
| US-9173953-B2 | Prodrugs containing an aromatic amine connected by an amido bond to a linker | ASCENDIS PHARMA AS (DK) | 2015-11-03 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20120156260-A1 | Prodrugs Containing an Aromatic Amine Connected By an Amido Bond to a Linker | ASCENDIS PHARMA A/S (DK) | 2012-06-21 | — | — | US | claimed |
| EP-2459227-A1 | PRODRUGS CONTAINING AN AROMATIC AMINE CONNECTED BY AN AMIDO BOND TO A LINKER | Ascendis Pharma A/S (DK) | 2012-06-06 | — | — | EP | claimed |
| US-6403589-B1 | NUCLEOSIDE TRANSPORT INHIBITOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-06-11 | — | — | US | claimed |
| EP-0999840-A1 | USE OF DRAFLAZINE-ANALOGUES FOR TREATING PAIN | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-05-17 | — | — | EP | claimed |
| EP-0814810-A4 | ADENOSINE AS A POSITIVE INOTROP IN THE COMPROMISED HEART | UNIV MASSACHUSETTS MEDICAL (US) | 1999-06-09 | — | — | EP | claimed |
| WO-1998057643-A1 | USE OF DRAFLAZINE-ANALOGUES FOR TREATING PAIN | JANSSEN PHARMACEUTICA N.V. (BE) | 1998-12-23 | — | — | WO | claimed |
| WO-1998019540-A1 | IN VIVO SELECTION OF PRIMITIVE HEMATOPOIETIC CELLS | SAINT JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 1998-05-14 | — | — | WO | claimed |
| EP-0814810-A1 | ADENOSINE AS A POSITIVE INOTROP IN THE COMPROMISED HEART | UNIVERSITY OF MASSACHUSETTS MEDICAL CENTER (US) | 1998-01-07 | — | — | EP | claimed |
| US-5629298-A | INCREASING CONTRACTILE PERFORMANCE, ADENOSINE TRANSPORT INHIBITORS USED AS POTENTIATORS | UNIVERSITY OF MASSACHUSETTS MEDICAL CENTER (US) | 1997-05-13 | — | — | US | claimed |
| WO-1996028163-A1 | ADENOSINE AS A POSITIVE INOTROP IN THE COMPROMISED HEART | UNIVERSITY OF MASSACHUSETTS MEDICAL CENTER (US) | 1996-09-19 | — | — | WO | claimed |
| EP-0577171-A2 | Use of piperazine acetamide derivatives against reperfusion damage | JANSSEN PHARMACEUTICA N.V. (BE) | 1994-01-05 | — | — | EP | claimed |
| WO-1991007967-A2 | METHOD OF PREVENTING OR LIMITING REPERFUSION DAMAGE | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-06-13 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120156260-A1 | Prodrugs Containing an Aromatic Amine Connected By an Amido Bond to a Linker | DAO, DNPEP, DDC | SLC29A1 98/4885KCNH2 1891/4885SLC6A3 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.